Solstice Oncology Raises $225M to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Event summary
- Solstice Oncology, a partner of Harbour BioMed, secured $225 million in Series A funding led by RA Capital Management.
- The financing will support the development of Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, in the neoadjuvant setting.
- Phase 2 trial of Porustobart in combination with pembrolizumab for MSS colon cancer will begin enrollment in Q4 2026.
- Porustobart demonstrated a 30% objective response rate in late-line MSS metastatic colorectal cancer patients in a prior Phase 2 study.
The big picture
The $225 million Series A funding for Solstice Oncology underscores the growing interest in neoadjuvant immuno-oncology therapies, particularly those targeting microsatellite-stable (MSS) colon cancer, a segment with limited treatment options. The strategic focus on earlier intervention in cancer treatment aligns with broader industry trends toward improving cure rates and long-term survival through innovative combination therapies. The involvement of leading investors like RA Capital Management highlights the potential scalability and market opportunity of Porustobart.
What we're watching
- Clinical Trial Progress
- The pace at which Solstice Oncology enrolls patients and generates data from the Phase 2 trial of Porustobart in MSS colon cancer will be critical to assess.
- Market Differentiation
- Whether Porustobart can establish itself as a differentiated CTLA-4 antibody in the competitive immuno-oncology landscape.
- Strategic Partnerships
- How the collaboration between Harbour BioMed and Solstice Oncology evolves, particularly in expanding the development of Porustobart beyond the current indications.
Related topics